Midostaurin in indolent systemic mastocytosis patients: an open-label phase 2 trial

Publication date: Available online 8 June 2018
Source:Journal of Allergy and Clinical Immunology
Author(s): Bjorn van Anrooij, Joanne N.G. Oude Elberink, L.F. Span, Jan G.R. de Monchy, Stefano Rosati, André B. Mulder, Johanna C. Kluin-Nelemans

Teaser

This is the first report on a trial using a Kit D816V targeting drug in indolent systemic mastocytosis. The results indicate midostaurin to be effective in reducing symptom severity and improving quality of life.


https://ift.tt/2Jv0WYL